Natco Pharma

Quick check

The five things to look at first. Open one for more.

• DebtHigh safetyRated AA by ICRA.
• ResultsProfit fallingIn the Jun 2026 quarter, sales fell 45% and profit fell 57% from a year earlier.
• DilutionSome dilutionIssued 1.71 crore new shares in the last year (+11%), raising ₹1,279 Cr.
• PromotersSteadyThe promoters (founders or parent) own 49% of the company, about the same as in Jun 2025.
• ValuationNormal for this stockThe share trades at 13.6 times its yearly earnings (P/E), cheaper than 69% of the time in the last 5 years. Its usual P/E is about 19.

Natco Pharma against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)13.6 against a typical 34: cheaper than most peers (1st = cheapest).34th of 220
• Sales growth−44.7% against a typical +15.6% from a year earlier.185th of 197
• Profit growth−57.1% against a typical +18.9% from a year earlier.137th of 160
• Share price, 3 months−15.4% against a typical −0.5%.166th of 200
• Size₹ 14,189.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).35th of 199

Exchange filings and their impact on the company.

• 23 Oct 2026Committee Meeting UpdatesHigh impactNeutralPrice −0.2% on 26 Oct
  Natco allotted 1.71cr rights shares at Rs750, raising Rs1,279cr and diluting EPS ~8.7%.

  Natco Pharma's Fund Raising Committee on Oct 23, 2026 allotted 1,70,58,082 equity shares at Rs750 per share under its rights issue, raising about Rs1,279.4 crore. Paid-up capital rose from 17.91 crore shares to 19.62 crore shares. The cash strengthens the balance sheet but dilutes EPS by about 9%.

  Full analysisFiling
• 22 Oct 2026General UpdatesHigh impactNeutralPrice +0.1% that day
  Natco's Rs 1,279cr rights issue at Rs 750 closed on Oct 22, adding ~9.5% new shares.

  Natco Pharma closed its rights issue on October 22, 2026, after opening on October 12. The issue offered equity shares of Rs 2 face value at Rs 750 each for up to Rs 12,794 million (about Rs 1,279 crore). The proceeds will increase equity and cash on allotment, with about 1.71 crore new shares implying ~9.5% dilution.

  Full analysisFiling
• 19 Oct 2026Press ReleaseLow impactPositivePrice +2% that day
  Natco launched generic Carboplatin in the US in a small $27.8m market, adding modest incremental sales.

  Natco Pharma launched Carboplatin Injection, a generic of Paraplatin for advanced ovarian cancer, in the US through its US subsidiary in manufacturing collaboration with Teyro Labs, Chennai. The product addresses a critical shortage in the US market. It had estimated US sales of USD 27.8 million for the 12 months ending June 2026, implying only a small incremental opportunity for Natco.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Venkaiah Chowdary Nannapaneni

Chairman of the Board, Managing Director, Executive Director

Rajeev Nannapaneni

Chief Executive Officer, Vice Chairman of the Board, Executive Director

Amit Parekh

Chief Financial Officer

Linga Rao Donthineni

President - Technical Affairs, Executive Director

Potluri Sivaramakrishna Prasad

Executive Vice President - Corporate Engineering Services, Executive Director

Rajesh Chebiyam

Executive Vice President - Crop Health Sciences

Kalakuntla Srinivas Rao

Executive Vice President - Pharma Division

N. Sadasiva Rao

Executive Vice President - Corporate Affairs, Legal & Secretarial, Estate Management